You may have seen headlines about CAR-T therapy and other cell-based treatments being tested for autoimmune diseases like rheumatoid arthritis and lupus. Recently, several of these trials were halted, including two CAR-T programs from major pharmaceutical companies and a cell-based therapy from Artiva.
What does that mean for patients? Dr. Siddharth Tambar, a Chicago rheumatologist and regenerative medicine physician at Chicago Arthritis and Regenerative Medicine, explains why these treatments hold real promise and why they still need time.
What Is CAR-T Therapy?
CAR-T therapy is a form of immunotherapy. Doctors engineer immune cells so they attack specific targets in the body.
This approach has changed treatment for some types of cancer. Researchers are now studying whether it can help people with autoimmune conditions.
Why Autoimmune Disease Is Not the Same as Cancer
This is the most important point. Cancer and autoimmune disease need very different treatment goals.
The Goal in Cancer Treatment
In cancer, treatment aims to completely destroy the harmful cells. The more thorough the destruction, the better.
The Goal in Autoimmune Disease Treatment
In autoimmune disease, the immune system isn’t the enemy. It’s miscommunicating. It fails to regulate itself and starts attacking your own body.
Because so much of the immune system is involved, wiping it out isn’t the answer. The real goal is to re-educate it so it stops attacking itself.
How Current Autoimmune Treatments Work
For decades, autoimmune disease treatment has focused on calming an overactive immune system:
- Disease-modifying drugs (DMARDs) reduce overall immune activity
- Biologic medications block specific parts of the immune response in a more targeted way
These treatments help many patients control their disease. But they don’t actually teach the immune system to behave correctly. That’s where immunotherapy could someday make a difference.
A Closer Look at the Halted Artiva Trial
The Artiva treatment used a creative, multi-step approach:
- Preconditioning with chemotherapy. Patients first received strong chemotherapy drugs (fludarabine and Cytoxan) to suppress the immune system so it wouldn’t reject the treatment.
- Donor natural killer cells. Instead of the patient’s own cells, the therapy used natural killer cells sourced from umbilical cord products.
- Pairing with Rituxan. The cells were combined with Rituxan (rituximab), a medication that targets mature B cells. Rituxan alone is already used to treat rheumatoid arthritis and some cancers.
The idea was that adding the natural killer cells would disable B cells even more effectively than Rituxan alone.
Why This Approach May Be “Too Much”
The concept is interesting. But it delivers treatment the way doctors would treat cancer, with several powerful layers stacked together.
There may be a place for such intense therapy in rare, very aggressive autoimmune cases. However, most autoimmune patients don’t need a treatment that acts like a hammer. The aim isn’t to kill the immune system.
What the Future of Autoimmune Care May Look Like
Dr. Tambar believes cell-based treatments will likely become a standard part of autoimmune care. Future therapies may:
- Use your own cells rather than donor cells
- Retrain the immune system to regulate itself properly
- Be less cytotoxic, meaning less focused on destroying cells
- Offer more precision and fewer risks
How long will it take? It could be five years, or it could be twenty. Progress depends on how quickly researchers, drug companies, and even AI tools learn from early trials.
Today’s versions are basic, but they’re teaching researchers valuable lessons. The key takeaway for science: autoimmune diseases are not cancer, and treatments need to reflect that.
What This Means for Patients Today
If you live with an autoimmune condition, you don’t have to wait for future breakthroughs to feel better. Proven options are available now, and a rheumatology specialist can help you find the right approach.
Arthritis Care That Fits Your Needs
At Chicago Arthritis and Regenerative Medicine, our team offers comprehensive arthritis treatment in Chicago, including:
- Autoimmune disease treatment for conditions like rheumatoid arthritis, lupus, and psoriatic arthritis
- Osteoarthritis treatment for worn, painful joints
- Joint pain relief plans tailored to your goals
- Chronic pain management strategies
Where Regenerative Medicine Fits In
Regenerative medicine in Chicago is a separate area from the experimental cell therapies discussed above. Treatments such as PRP therapy (platelet-rich plasma) are used to support healing in joints and soft tissues, especially for osteoarthritis and injuries. Your physician can explain whether these options make sense for your condition.
Conclusion
Cell-based therapies and immunotherapy may one day transform how autoimmune diseases are managed. The recent halted trials don’t mean failure. They show that researchers are still learning how to treat autoimmunity on its own terms, with precision instead of brute force.
Until then, an experienced Chicago rheumatologist can help you manage your condition safely and effectively with today’s best options.
Ready to take the next step? Visit ChicagoArthritis.com to learn more about our approach to arthritis care, autoimmune disease treatment, and regenerative medicine, or to schedule a consultation.
Long-Term vs Short-Term Steroid Use in Autoimmune Conditions
Steroids for Rheumatoid Arthritis: Quick Relief or Long-Term Harm?